Print Page  |  Close Window


BioTelemetry provides cardiac monitoring services, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. Since the Company became focused on cardiac monitoring in 1999, the Company has developed a proprietary integrated patient management platform that incorporates a wireless data transmission network, Food and Drug Administration ("FDA") cleared algorithms and medical devices, and 24-hour digital monitoring service centers.

The Company operates under three segments: patient services, product and research services. The patient services segment is focused on the diagnosis and monitoring of cardiac arrhythmias, or heart rhythm disorders. The Company provides cardiologists and electrophysiologists who prefer to use a single source of cardiac monitoring services with a full spectrum of solutions, ranging from the differentiated Mobile Cardiac Outpatient TelemetryTM ("MCOT™") service to wEvent, event, Holter, Pacemaker and International normalized ratio ("INR") monitoring. INR monitoring is a measurement of blood coagulation in the circulatory system and is prescribed for patients on long term anticoagulation therapy. The product business segment focuses on the development, manufacturing, testing and marketing of medical devices to medical companies, clinics and hospitals. The research services segment is engaged in central core laboratory services providing cardiac monitoring, scientific consulting and data management services for drug and medical device trials.

Recent NewsMore >>
11/30/17BioTelemetry, Inc. Enters Agreement to Provide Cardiac Monitoring for Apple’s Heart Study
MALVERN, Pa., Nov. 30, 2017 (GLOBE NEWSWIRE) -- BioTelemetry, Inc. (NASDAQ:BEAT), the leading mobile and wireless medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, announced today a partnership with Apple (NASDAQ:AAPL) to provide cardiac monitoring services in conjunction with the Apple Heart Study.  The study, which launched today, is expected to discover undiagnosed irregular heart rhythms, such as atrial fibrillation... 
Printer Friendly Version
11/27/17Telcare, a Division of BioTelemetry, Inc., Announces Collaboration with Onduo in Diabetes Management Program
MALVERN, Pa., Nov. 27, 2017 (GLOBE NEWSWIRE) -- (NASDAQ:BEAT) – Telcare, the manufacturer of the world’s first FDA-cleared cellular-enabled blood glucose monitor, has entered into a strategic collaboration with Onduo, a joint venture created by Verily (an Alphabet company) and Sanofi.  Under this partnership, Telcare will serve as the supplier of remote blood glucose systems and the resulting data for patients enrolled in Onduo’s groundbreaking diabetes management program. Onduo will leverage... 
Printer Friendly Version
11/07/17BioTelemetry, Inc. Reports Third Quarter 2017 Financial Results
Company Posts Strong Growth with Integration Ahead of Schedule  Reports Record Quarterly Revenue and Adjusted EBITDA MALVERN, Pa., Nov. 07, 2017 (GLOBE NEWSWIRE) -- BioTelemetry, Inc. (NASDAQ:BEAT), the leading mobile and wireless medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, today reported results for the third quarter ended September 30, 2017. Company Highlights Recognized highest quarterly revenue in Co... 
Printer Friendly Version
10/30/17BioTelemetry, Inc. to Release Third Quarter 2017 Earnings Results on November 7, 2017
MALVERN, Pa., Oct. 30, 2017 (GLOBE NEWSWIRE) -- BioTelemetry, Inc. (NASDAQ:BEAT) will release its third quarter 2017 earnings on Tuesday, November 7th at 4:00 PM Eastern Time. The BioTelemetry quarterly conference call will be held at 5:00 PM Eastern Time, Tuesday, November 7, 2017.  The broadcast will be available through the investor information section of the BioTelemetry website  If you are unable to participate during the live webcast, an archive will be available on our... 
Printer Friendly Version

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.